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Abstract
Background Tissue liquefaction technology (TLT) deliv-
ers warmed saline from the liposuction cannula tip at low
pressure pulses to disaggregate adipocytes. This technol-
ogy differs significantly from that used in other liposuction
devices including water jet-assisted liposuction. Here we
introduce our early experience with this technology in the
setting of fat transfer for revision breast reconstruction.
Methods A retrospective chart review of 136 consecutive
patients who underwent fat harvest with TLT and subse-
quent transfer into 237 breast reconstructions was con-
ducted at a single institution. This two-surgeon series
examined donor and recipient site complication rates over a
median follow-up of 143 days [87–233].
Results The overall complication rate was 28.7 %, of
which the majority (22.1 %) was fat necrosis at the
recipient site as documented by any clinical, imaging, or
pathologic evidence. The abdomen served as the donor site
for half of the cases. Donor site complications were limited
to widespread ecchymosis of the donor site notable in
10.4 % of cases. Twenty-five percent of patients had
received postmastectomy radiotherapy prior to fat transfer.
Prior to revision with fat transfer, implant-based breast
reconstruction was used in 75.5 % of cases, and autologous
flaps in the remainder. Fat transfer was combined with
other reconstructive procedures 94.1 % of the time.
Conclusions TLT can be used to harvest adipocytes for fat
transfer with donor site morbidity and recipient site
complications comparable to other modalities. The effi-
ciency and quality of harvested fat makes this technology
appealing for wide spread adoption during fat transfer.
Level of Evidence IV This journal requires that the authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
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Introduction
Autologous fat transfer continues to increase in popularity as
a powerful tool to revise the contour of the face, trunk, and
extremities. In aesthetic surgery, 85 % of American Society
of Plastic Surgeons (ASPS) members now use fat grafting at
least some of the time during rhytidectomy [50] and 28 %
use fat grafting in aesthetic breast surgery [29]. Fat transfer
is also widely utilized in breast reconstruction, where it is
employed at least part of the time by 62 % of ASPS
membership [54]. The indications for fat transfer have
expanded past the face and breasts to include rejuvenation of
the hands [14] and lips [15], recontouring of scars [30],
gluteal augmentation [55], and penile enlargement [41]. In
addition to contour correction or volume augmentation, fat
transfer may have a role in ameliorating some of the effects
of radiation-induced cutaneous fibrosis [53].
Key to the expanded application of fat transfer for aes-
thetic and reconstructive indications are its safety, efficacy,
and efficiency. Clinical studies suggest that fat transfer is an
oncologically safe technique following mastectomy whereby
recurrence rates do not statistically significantly differ
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between engrafted and naı¨ve cohorts [16, 42]. By contrast,
some clinical data following lumpectomy [42–44] as well as
studies in animal and in vitro models suggest that fat transfer
may potentiate the malignant behavior of active breast
cancer cells. This may be mediated by adipose-derived stem
cells or growth factors elaborated by transferred adipocytes
[10, 23, 32–34, 37, 48, 60, 61]. These findings require more
thorough investigation, particularly in clinically relevant
models.
Current literature suggests that the efficacy of fat
grafting is highly variable, with graft take ranging from 20
to 80 % [22, 31]. As a result, plastic surgeons often counsel
patients that only half of the transferred fat will engraft.
There are multiple disparate factors contributing to optimal
conditions for fat graft survival including donor site
[39, 56], medications utilized in tumescence solution
[17, 25], aspiration pressure [49], reinjection rate [13, 38],
fat harvesting technique [8, 24], and recipient site factors
[26–28]. The efficient harvest, processing, and reinjection
of fat, while less commonly discussed, are also important
for the long-term success of this technique [29]. Shortening
the duration that harvested adipocytes reside ex vivo may
optimize the proportion remaining viable upon reinjection
resulting in better retention and less fat necrosis. Improved
efficiency also impacts cost by shortening operative times
and minimizing the need for additional fat processing steps
that precede reinjection of harvested fat.
We report on the utility of tissue liquefaction technology
(TLT; HydraSolve Lipoplasty System; Andrew Technolo-
gies, Irvine, CA) to harvest fat for subsequent transfer.
Originally developed for cataract surgery in 2003, tissue
liquefaction lipoplasty (TLL) selectively liquefies adipose
tissue using warmed saline (37–55 C) delivered in low
pressure pulses (300–1100 psi) administered within the
liposuction cannula tip. Energy from the device is sufficient
to disaggregate adipocytes into 0.5–2.0 mm clusters while
reportedly maintaining the integrity of cell membranes,
blood vessels, nerves, and connective tissues. Minimal soft
tissue disruption, swelling, pain, heat transfer, and ecchy-
mosis, along with less surgeon fatigue and efficient fat
harvest with reduced fibrous tissue in the resulting graft
material are suggested advantages of TLL. The following is
the first report using TLT to harvest fat for subsequent




A retrospective chart review of 136 consecutive patients
was conducted following approval by our institutional
review board (IRB# 201505068). TLT was used in all
subjects to harvest adipocytes for revision fat grafting after
previous autologous or implant-based breast reconstruc-
tion. Procedures were performed at a single institution from
March 2013 to March 2015. Patients whose fat was har-
vested by any other method or transferred for any reason
other than refinement of an ipsilateral breast reconstruction
were excluded.
Study Design
Patient characteristics of interest included age, body mass
index (BMI), smoking status, and comorbidities (i.e., dia-
betes and hypertension). Smoking status was classified into
three different groups: patients who never smoked, patients
who quit at least 1 month prior to surgery, and current
smokers. Adjunctive clinical information included tumor
side, type of breast reconstruction (implant based or
autologous), donor region for fat harvest, volume of
tumescence solution, volume of fat graft injected, duration
of surgery, ecchymosis at the donor region, radiotherapy,
complications, and follow-up time.
Ecchymosis was classified into three groups: ‘‘minimal’’
which was patchy discoloration\25 cm2; ‘‘moderate’’
which was continuous discoloration[25 cm2; and ‘‘wide-
spread’’ which was uniform discoloration of the donor
region or expansion of ecchymosis to an adjacent anatomic
regions beyond a zone of adherence. Although any com-
plication documented in the medical record was recorded,
only fat necrosis was found in greater than two patients. Fat
necrosis diagnosed by clinical exam alone, was differen-
tiated from additional cases of fat necrosis identified with
imaging (mammography, ultrasound, or MRI). Follow-up
time was measured in days from the date of fat grafting
procedure to the last clinic visit. Outcome measures of
interest included fat necrosis, ecchymosis overlying the
region of fat harvest, and any adverse events such as deep
vein thrombosis (DVT).
Liposuction and Fat Grafting Technique
Most of the fat grafting procedures were performed at the
time of scar revision, minor contour revisions of the flap, or
nipple reconstruction. General anesthesia was utilized for
all patients. Tissues were infiltrated 15 min prior to harvest
utilizing the ‘‘super wet’’ technique with a wetting solution
consisting of lactated ringers combined with 15 ml of 1 %
lidocaine, and 1 ampule of 1:1000 epinephrine per liter
[51]. Cannula sizes from 3–4 mm were used according to
the donor site. The donor site was selected based on
physical exam confirmation of adequate adipose tissue and
patient preference. TLT was performed with the Hydra-
Solve Lipoplasty System (Andrew Technologies, Irvine,
Aesth Plast Surg (2016) 40:854–862 855
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CA) in all cases. The device phaser stream was heated to
120–130 F and a pressure of 900–1100 psi. Harvested fat
was separated exclusively with subsequent gravity filtration
in a large sterilized Wells–Johnson (Tuscon, AZ) canister
for C10 min with no further centrifugation. The infranatant
aqueous layer was poured off and the supernatant fat
transferred into syringes for reinjection in 0.1–1.0 cc ali-
quots. Fat was injected into areas of contour irregularity
and implant visibility usually in the superior and medial
aspect of the reconstructed breast.
Statistical Analysis
None of the continuous variables were normally dis-
tributed, and so medians with interquartile ranges were
reported. Descriptive statistics were calculated for demo-
graphic and clinical characteristics. Categorical variables
were compared using a Pearson’s Chi-squared test.
Adjusted odds ratios and 95 % confidence intervals were
calculated for each independent variable for logistic
regression analysis. A patient-level logistic regression was
done to evaluate the association between fat necrosis and
age, BMI, smoking status, diabetes mellitus, and hyper-
tension. A breast-level logistic regression was performed to
evaluate the association between fat necrosis and recon-
struction type, fat donor area, fat graft volume, radiation,
and the existence of tumor. Another logistic regression was
performed to study the relationship between widespread
ecchymosis of the donor area in patients with variables
such as age, BMI, tumescence volume, fat graft volume,
and duration of surgery. Statistical significance was set at a
p value of\0.05. Statistical analyses were performed using
SPSS 23 software (IBM, Armonk, NY).
Results
Patient Characteristics
TLT was performed by two plastic surgeons (T.M.M. &
M.M.T) to harvest fat grafts as a method to revise breast
reconstruction in 136 consecutive patients over a two-year
period. Summarized in Table 1, the median age of the
patients was 48 years old and median BMI was 26.8 kg/
m2. There were only 2 current smokers among all patients.
Fifty-eight patients (24.5 %) received radiotherapy prior to
fat grafting. In 179 breasts (75.5 %) fat was injected
around the implant and in 58 breasts (24.5 %) into autol-
ogous flaps. Among autologous flaps 67.2 % (n = 39)
were DIEP flaps, 15.5 % (n = 9) were latissimus flaps, and
10.3 % (n = 6) were free TRAM flaps. The abdomen was
utilized as the donor site for fat grafts in 48.5 % of cases,
followed by the flanks (28.7 %) or a combination of the
flanks, abdomen, thigh, and bra strap roll (22.8 %). Median
volume of the tumescence solution used per patient was
1500 ml. Median volume of fat graft injected per breast
was 90 ml. Median duration of procedures where fat
transfers were performed with TLT was 79 min. Impor-
tantly, fat transfer was combined with other reconstructive
procedures to revise the reconstructed breast or improve
symmetry of the contralateral side 94.1 % of the time.
Implant exchange (66.5 %), nipple reconstruction
(27.1 %), and a contralateral augmentation, mastopexy, or
reduction (18.7 %) were the most common accompanying
procedures and contributed to the duration of the procedure
as they were usually being concomitantly performed.
Median follow-up after fat transfer was 143 days.
Complications
Among 136 patients, 97 (71.1 %) had minimal donor site
ecchymosis. Twelve (8.8 %) patients were noted to have
fat necrosis by clinical exam, while an additional 18
(13.3 %) were considered to have fat necrosis based on
review of additional breast imaging studies for a total of 30
(22.1 %) patients (Table 2). Among 237 breasts, fat
necrosis was found in 31 breasts (13.1 %) but was clini-
cally evident in only 15 (6.3 %). There were no incidents
of cellulitis, hematoma, or wound dehiscence at the donor
site where TLL was performed. At the recipient site,
complications were rare but included hematoma requiring
evacuation (n = 2), cellulitis (n = 2), and wound dehis-
cence (n = 2). A single DVT occurred without progression
to pulmonary embolism. There was no statistically signif-
icant difference between patients who did and did not
experience fat necrosis according to age, BMI, comor-
bidities, smoking status, history of radiotherapy, recon-
struction type, liposuction region, tumescence volume, fat
graft volume, and operation duration (Table 1). Patients
who had fat necrosis had significantly longer follow-up
than patients who did not (198 vs. 135 days, p = 0.005).
Logistic regression analysis of all patient cohorts
(n = 136) found no statistically significant relationship
between fat necrosis and the variables seen in Fig. 1.
Another logistic regression analysis in breasts (n = 237)
found no statistically significant relationship between fat
necrosis and reconstruction type, donor site, fat graft vol-
ume, radiotherapy, and history of tumor with previous
therapeutic versus prophylactic mastectomy (Fig. 2).
Minimal donor site ecchymosis was noted in 71.1 % of
patients (n = 96), moderate ecchymosis in 18.5 %
(n = 25), and widespread ecchymosis in only 10.4 %
(n = 14). A logistic regression analysis performed in this
patient cohort (n = 136) found that among variables
856 Aesth Plast Surg (2016) 40:854–862
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documented in Fig. 3, only BMI over 30 kg/m2 had a
significant impact (p = 0.04), decreasing the odds ratio of
widespread ecchymosis by 0.10 (95 % CI 0.01–0.87).
Discussion
This study shows our early two-surgeon experience when
TLL was used to harvest adipocytes for transfer to achieve
contour correction in women having undergone prosthetic
or autologous breast reconstruction. Over a 2-year period,
TLL was safely used to harvest adipocytes for fat grafting
to the reconstructed breast in 136 consecutive cases. The
only significant systemic adverse event was a single case of
Table 1 Demographic and clinical characteristics organized by development of fat necrosis
Fat necrosis






















DM 7 (5.9) 5 (5.7) 2 (6.7) 0.468
CHF 25 (18.4) 21 (19.8) 4 (13.3) 0.311
Smoking 0.775
Never 103 (75.7) 81 (76.4) 22 (73.3)
Prior 31 (22.8) 23 (21.7) 8 (26.7)
Current 2 (1.5) 2 (1.9) 0
Radiotherapy to breast 0.542
Yes 58 (24.5) 49 (24.4) 9 (25)
No 179 (75.5) 152 (75.6) 27 (75)
Reconstruction type per breast (n = 237) 0.84
Implant 179 (75.5) 151 (75.1) 28 (77.8)
Autologous 58 (24.5) 50 (24.9) 8 (22.2)
Liposuction region 0.702
Abdomen 66 (48.5) 53 (50) 13 (43.3)
Flank 39 (28.7) 30 (28.3) 9 (30)
Others (Thigh, bra strap) 6 (4.4) 5 (4.6) 1 (3.3)
2 or more regions 25 (18.4) 18 (27.1) 7 (23.4)




























Table 2 Fat transfer complications at the recipient site when using
tissue liquefaction technology (TLT) for graft harvest
Complications
Fat necrosis
Clinically exam only 12 (8.8 %)
Clinical exam ? imaging (MRI/ultrasound) 30 (22.1 %)
Hematoma 2 (1.5)
Cellulitis 2 (1.5)




No complications were noted at the donor site
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DVT (0.74 %) without pulmonary embolism. Consistent
with our findings, in the liposuction population, venous
thromboembolic events (VTE) occur in 0–1.1 % of the
large volume liposuction cases [3, 6, 19] According to the
National Surgical Quality Improvement Program (NSQIP)
database, patients who have undergone mastectomy with
immediate reconstruction will experience a DVT within
30 days in 0.41–0.52 % of cases, [36] and later DVTs are
Fig. 1 Regression analysis of fat necrosis adjusted to diabetes mellitus, hypertension, age, smoking status, and BMI stratification by patient
(n = 136)
Fig. 2 Regression analysis of
fat necrosis adjusted to breast
reconstruction method, fat
donor region, volume of fat
graft, and radiotherapy by breast
(n = 237)
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unsettlingly frequent in patients with a former malignancy,
even after tumor resection [1]. Fat transfer was often
combined with other breast reconstruction revisions
including nipple reconstruction, capsulorrhaphy, or a con-
tralateral breast augmentation, reduction, or mastopexy to
improve symmetry. While we are unaware of any data to
suggest that combining fat transfer with other reconstruc-
tive breast procedures increases VTE events, there is strong
evidence in the aesthetic surgery literature to suggest that
performing concurrent procedures increases the risk of
VTE complications [4, 21, 58].
There were no significant donor site-associated com-
plications in this series. None of the patients developed a
hematoma requiring evacuation or cellulitis at their donor
sites and 71.1 % exhibited only minimal ecchymosis. We
concede that the degree of ecchymosis is prone to inter-
pretation, particularly in a retrospective review. Still, the
degree of ecchymosis identified in our series is consistent
with that reported by a prospective randomized control trial
that found ‘‘less’’ ecchymosis following both suction- and
laser-assisted lipoplasty [45]. Interestingly, obesity signif-
icantly reduced the risk of developing widespread ecchy-
mosis in our study. We doubt that an elevated BMI has a
protective effect on bleeding caused by TLL. Rather, any
minor bleeding caused by TLL is more readily concealed in
the larger volume of adipose tissue that would commonly
characterize an individual with a higher BMI.
Cellulitis, hematoma, and incisional dehiscence all
occurred at a rate of\2 % at the recipient site and were not
attributable to TLL. We identified fat necrosis in 22.1 % of
patients by clinical exam or imaging. Fat necrosis, or
downstream sequela-like oil cysts and microcalcifications
which were included as fat necrosis events in this series,
are known to occur in 3.9 [62] to 47 % of patients [18],
with a recent review reporting mammographic evidence of
clear cystic lesions in 25 % of patients receiving fat
transfer to the breast in a mixed cohort of aesthetic and
reconstructive cases [57]. We recognize that the incidence
of fat necrosis identified by our study is subject to criti-
cism, and even when diagnosed by imaging, may be
dependent on the modality utilized. For example, while
microcalcifications were identified by mammography in
19 % of patients in one series, cystic lesions were identified
in 47 % of these patients by magnetic resonance imaging
[18]. Our data are relatively consistent with these reports
noting that we found clinical evidence of fat necrosis in
8.8 % of patients, or 6.3 % of breasts, with a substantial
increase in sensitivity for this finding afforded by further
imaging. Our data are consistent with other reports sug-
gesting that the harder you look for fat necrosis with
multimodality imaging, the more likely you are to find it
[7, 18]. The clinical impact of fat necrosis in this study was
modest, as only 4 (2.9 %) patients required operative
excision—two to rule out malignancy and two to address
uncomfortable induration. There was also a correlation
between the recognition of fat necrosis and longer follow-
up (p = 0.005). This may be due to a combination of
factors like a greater number of opportunities for clinical
and radiographic surveillance, as well as uncovering areas
of fat necrosis previously concealed by surrounding swel-
ling. Interestingly, we did not find a higher rate of fat
necrosis with increasing volumes of fat transferred. Safe
transfer of larger volumes of fat may be attributable to
careful preparation of the recipient space [26].
Suction-, ultrasound-, and water jet-assisted liposuction
are current methods for fat transfer, and each is supported by
several studies examining their impact on harvested adipo-
cyte viability [2]. Compared to en bloc resected fat, adipo-
cytes harvested with SAL possess proportionately fewer
adipose-derived stem cells, but those harvested without SAL
Fig. 3 Regression analysis of severe ecchymosis of donor area adjusted to age, BMI, tumescence volume, fat graft volume, and duration of
surgery in patients (n = 136)
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possess similar viability and differentiation characterization
[12]. This detailed analysis by Duscher et al. verifies that
SAL is an effective method of fat harvest for cell-based
therapies [12]. Ultrasound-assisted suction lipectomy (UAL)
initiates the rapid rarefaction and compression of tumes-
cence fluid bubbles—lodged between adipocytes—to reso-
nant size. Adipocytes are dislodged by these rapidly
enlarging fluid bubbles (stable cavitation) and then dispersed
with the tumescence solution via acoustic streaming [47]. A
lipolysis assay of fat harvested using UAL at an amplitude
of 60 % suggested that 85.1 % of harvested adipocytes were
viable and metabolically active [47]. Propidium iodide
staining, an alternative methodology, suggested that 88.7 %
of adipocytes were viable, while previous work suggests that
UAL does not adversely impact the proliferative or osteo-
genic capacity of adipose-derived stem cells [40]. An ele-
gant series of experiments recently demonstrates that
lipoaspirates harvested with UAL and SAL share a similar
proportion of viable adipose-derived stem cells with equiv-
alent expression of regenerative genes and potential to dif-
ferentiate into chondrocytes, adipocytes, or osteocytes [11].
Another technology, water jet-assisted liposuction (WAL)
uses a dual-aperture cannula that simultaneously emits
tumescence solution as a fan-shaped, pulsating jet through
an anteriorly located aperture, and suction fluid and aspi-
rated fat from a more posteriorly located side port
[35, 46, 59]. Human fat harvested with WAL demonstrated
greater viability using both colorimetric and glucose trans-
port test assays, with greater retention by weight, less
apoptosis by Annexin V expression, and increased revas-
cularization by CD31 immunostaining when injected as a
xenograft into a murine host [59]. Other work has suggested
that fat harvested with WAL contains abundant
CD34? cells suggesting a stem cell-rich stromal vascular
fraction although a control group was not utilized in this
study [35]. Although human data are not available, rats
engrafted with human adipose xenografts harvested with
TLL demonstrate adipocyte viability, graft weight, and
histology comparable to the Coleman technique [9]. To truly
compare the efficacy of one of these techniques over
another, a single study that utilizes the same outcome met-
rics and units of measure is required. In addition, while
optimized fat graft retention relies, at least in part, on the
viability of harvested adipocytes [52], the maintenance of
volume correction conferred by fat transfer likely also relies
on fibrotic ingrowth and ghost cells [20].
Practical considerations like efficiency and cost effec-
tiveness accompany the ability of a liposuction device to
harvest adipocytes for fat transfer. Harvested fat can be
prepared in several ways including centrifugation, gauze
rolling, gravity separation, or proprietary fat processing
devices [5, 29]. Large volume fat transfers, in particular, can
be time consuming and potentially tedious. In a recent study
that compared the RevolveTM (Acelity, NJ) fat processing
device to the Coleman technique, the additional consumable
cost of the RevolveTM device was felt to be economically
justified for planned transfers greater than 75 cc and oper-
ative times were noted to be 10–20 min shorter [5]. In our
series, fat harvested with TLT was collected in a large,
reusable, sterilized canister and subjected to gravity filtration
for at least 10 min. Fat transfer was accompanied by con-
current revision procedures 94.1 % of the time in our study
and yet the median total operative time was 79 min with an
interquartile range of 60–150 min. As such, the ‘‘downtime’’
that may have occurred waiting for gravity filtration to occur
was actually occupied by other revision procedures. In
addition, recognizing that these ancillary procedures inclu-
ded implant exchanges, nipple reconstructions, and in many
cases, breast reductions, augmentation, or mastopexies, we
felt that the incorporation of TLT with gravity filtration into
our fat transfer regimen was suitably efficient. After dis-
carding the aqueous infranatant, we transferred a median of
90 cc of adipose tissue per breast, and were able to do this
without any other processing step. Moreover, adipocytes
were suctioned in a closed system directly into a canister and
then collected into syringes leading to fewer opportunities
for bacterial contamination and loss of harvested fat due to
leakage or spills.
This series is the first to report on the use of TLT for fat
transfer but further work will establish its value as an
addition to the liposuction and fat transfer device arma-
mentarium. This study is subject to the inherent weak-
nesses of a retrospective review, and in particular the
ability to precisely quantify the degree of ecchymosis, fat
necrosis, graft retention, and patient satisfaction. Balancing
the efficiencies and outcomes derived from using this
technology versus the capital and consumable costs of this
device requires a formal cost analysis. Moreover, our study
lacks a control group that keeps other variables constant
and employs a technique like standard suction-assisted
lipectomy to compare to TLT. The viability of adipocytes,
characteristics of the stromal vascular fraction, and degree
and long-term durability of contour correction using fat
harvested by TLT should be directly compared to an SAL
control group as well as other harvesting technologies like
WAL and UAL. A real-world cost analysis rather than
application of a theoretical model to evaluate direct hos-
pital costs and physician reimbursement when using TLT
versus other technologies would also be of value.
Conclusions
We present the first experience with TLL to harvest adi-
pocytes for fat transfer in postmastectomy breast recon-
struction revision. TLL was well tolerated with a low
860 Aesth Plast Surg (2016) 40:854–862
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incidence of donor site ecchymosis and fat necrosis rates
consistent with other fat harvest techniques. In addition to
aesthetic liposuction, TLL represents a viable option to
harvest fat for lipofilling in breast reconstruction.
Compliance with Ethical Standards
Disclosure TM and MT have received consulting fees from Andrew
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